Screener
Kymera Therapeutics KYMR Balance Sheet Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $373.37M+231% | $124.48M-62.9% | $144.09M+60.2% | $357.01M+197% | $112.95M+2.0% | ||
| $597.84M+52.2% | $566.51M+71.9% | $506.84M+35.8% | $491.27M+33.3% | $392.73M-10.6% | ||
| $998.59M+89.0% | $737.27M+1.2% | $677.43M+35.2% | $871.21M+70.7% | $528.3M-7.1% | ||
| $38.24M-15.3% | $39.97M-17.7% | $41.62M-15.4% | $43.18M-14.4% | $45.13M-11.9% | ||
| $1.77B+60.4% | $1.65B+45.5% | $1.67B+81.7% | $1.74B+78.2% | $1.1B+6.5% | ||
| $11.92M+117% | $8.92M+54.3% | $12.84M+25.1% | $4.02M-33.0% | $5.51M-15.2% | ||
| $0-100% | $0-100% | $0-100% | $22.93M+68.9% | $23.28M+16.3% | ||
| $1.37M-27.5% | $1.58M-17.0% | $1.7M+9.1% | $1.82M+19.6% | $1.89M+40.7% | ||
| $89.72M+25.4% | $71.33M-18.5% | $62.64M+6.2% | $83.21M+22.8% | $71.58M+7.6% | ||
| $152.74M-2.0% | $136.19M-14.7% | $129.38M-2.0% | $163.15M+14.6% | $155.79M+9.8% | ||
| $9K+28.6% | $8K+14.3% | $8K+14.3% | $8K+14.3% | $7K0.0% | ||
| -$1.33B-35.7% | -$1.2B-33.4% | -$1.14B-38.4% | -$1.07B-41.3% | -$978.98M-43.2% | ||
| $1.61B+70.6% | $1.51B+55.4% | $1.54B+95.8% | $1.58B+89.0% | $946.26M+6.0% | ||
| $1.77B+60.4% | $1.65B+45.5% | $1.67B+81.7% | $1.74B+78.2% | $1.1B+6.5% |
FAQ
- What are Kymera Therapeutics's total assets?
- Kymera Therapeutics (KYMR) holds $1.8B in total assets, up 60.4% year over year.
- How much debt does Kymera Therapeutics have?
- Kymera Therapeutics carries $78.0M in total debt against $1.6B of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Kymera Therapeutics have?
- Kymera Therapeutics holds $373.4M in cash and equivalents.
- Can Kymera Therapeutics cover its short-term obligations?
- Its current ratio is 11.13 — current assets exceed current liabilities.
- Where does Kymera Therapeutics's balance sheet data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
